Cargando…

Quantifying HER-2 expression on circulating tumor cells by ACCEPT

Circulating tumor cells (CTCs) isolated from blood can be probed for the expression of treatment targets. Immunofluorescence is often used for both the enumeration of CTC and the determination of protein expression levels related to treatment targets. Accurate and reproducible assessment of such tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeune, Leonie, van Dalum, Guus, Decraene, Charles, Proudhon, Charlotte, Fehm, Tanja, Neubauer, Hans, Rack, Brigitte, Alunni-Fabbroni, Marianna, Terstappen, Leon W. M. M., van Gils, Stephan A., Brune, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662084/ https://www.ncbi.nlm.nih.gov/pubmed/29084234 http://dx.doi.org/10.1371/journal.pone.0186562

Ejemplares similares

Classification of Cells in CTC-Enriched Samples by Advanced Image Analysis
por: de Wit, Sanne, et al.
Publicado: (2018)

Metastasis and Circulating Tumor Cells
por: van Dalum, Guus, et al.
Publicado: (2012)

Detection of Circulating Tumor Cells
por: de Wit, Sanne, et al.
Publicado: (2014)

Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patients
por: Nanou, Afroditi, et al.
Publicado: (2018)

Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients
por: Alunni-Fabbroni, Marianna, et al.
Publicado: (2018)

HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer
por: Nanou, Afroditi, et al.
Publicado: (2020)

Leukocyte-Derived Extracellular Vesicles in Blood with and without EpCAM Enrichment
por: Nanou, Afroditi, et al.
Publicado: (2019)

Filtration Parameters Influencing Circulating Tumor Cell Enrichment from Whole Blood
por: Coumans, Frank A. W., et al.
Publicado: (2013)

Filter Characteristics Influencing Circulating Tumor Cell Enrichment from Whole Blood
por: Coumans, Frank A. W., et al.
Publicado: (2013)

How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018)

LKB1 pro‐oncogenic activity triggers cell survival in circulating tumor cells
por: Trapp, Elisabeth Katharina, et al.
Publicado: (2017)

Detection of circulating tumor cells in colorectal cancer patients using the GILUPI CellCollector: results from a prospective, single‐center study
por: Dizdar, Levent, et al.
Publicado: (2019)

EpCAM(high) and EpCAM(low) circulating tumor cells in metastatic prostate and breast cancer patients
por: de Wit, Sanne, et al.
Publicado: (2018)

Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patients
por: Mendelaar, Pauline A. J., et al.
Publicado: (2020)

The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

A high-throughput DNA methylation analysis of a single cell
por: Kantlehner, Martin, et al.
Publicado: (2011)

Tumour-derived extracellular vesicles in blood of metastatic cancer patients associate with overall survival
por: Nanou, Afroditi, et al.
Publicado: (2020)

Circulating Cell-Free DNA Combined to Magnetic Resonance Imaging for Early Detection of HCC in Patients with Liver Cirrhosis
por: Alunni-Fabbroni, Marianna, et al.
Publicado: (2021)

Is the (Neo)adjuvant Therapy of Patients with Primary HER2-positive Breast Cancer Cost-Covering?: Process Cost Analysis of Neoadjuvant and Post-Neoadjuvant Systemic Therapy of Patients with Primary HER2-positive Breast Cancer
por: Krawczyk, Natalia, et al.
Publicado: (2022)

53BP1 Accumulation in Circulating Tumor Cells Identifies Chemotherapy-Responsive Metastatic Breast Cancer Patients
por: Schochter, Fabienne, et al.
Publicado: (2020)

Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer – Results of the German SUCCESS-A- trial
por: Jueckstock, Julia, et al.
Publicado: (2016)

Methylation patterns in serum DNA for early identification of disseminated breast cancer
por: Widschwendter, Martin, et al.
Publicado: (2017)

Deciphering HER2-HER3 Dimerization at the Single CTC Level: A Microfluidic Approach
por: Tulukcuoglu Guneri, Ezgi, et al.
Publicado: (2022)

How sticky are our proteins? Quantifying hydrophobicity of the human proteome
por: van Gils, Juami Hermine Mariama, et al.
Publicado: (2022)

Real-world data on discordance between estrogen, progesterone, and HER2 receptor expression on diagnostic tumor biopsy versus tumor resection material
por: Berghuis, A. M. Sofie, et al.
Publicado: (2019)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer—a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
por: de Gregorio, Amelie, et al.
Publicado: (2022)

Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
por: Andree, Kiki C., et al.
Publicado: (2018)

Tumor-Associated Macrophages—Implications for Molecular Oncology and Imaging
por: Kimm, Melanie A., et al.
Publicado: (2021)

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies
por: Krawczyk, Natalia, et al.
Publicado: (2022)

Quantifying acceptable artefact ranges for dermatologic classification algorithms
por: Petrie, T.C., et al.
Publicado: (2021)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast Cancer
por: Jäger, Bernadette A.S., et al.
Publicado: (2015)

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
por: Fehm, Tanja, et al.
Publicado: (2012)

Identifying Mitotic Kinesins as Potential Prognostic Biomarkers in Ovarian Cancer Using Bioinformatic Analyses
por: Liu, Hailun, et al.
Publicado: (2022)

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
por: Jaeger, B. A. S., et al.
Publicado: (2017)

NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
por: Geyer, Thomas, et al.
Publicado: (2021)

Quantifying compliance and acceptance through public and private social conformity
por: Sowden, Sophie, et al.
Publicado: (2018)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_f5ak2qta8eapu42m9i87cqqif1